Gilgamesh Pharma Inc. — Form D
Gilgamesh Pharma Inc. of NEW YORK, NY, a company, filed a Form D exempt-offering notice with the SEC on 2026-03-24. The offering totals $60.0M, of which $60.0M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2026-03-24
- Form: D
- Accession: 0002107396-26-000003
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $60.0M
- Amount sold: $60.0M
- Minimum investment: $50K
- Investors: 40
- Date of first sale: 2026-03-09
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-577482
Issuer
- Name: Gilgamesh Pharma Inc.
- CIK: 0002107396
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2025
- Address: 113 UNIVERSITY PLACE, SUITE 1019, NEW YORK, NY, 10003
- Phone: 929-723-4861
Officers, directors & promoters (8)
| Name | Role | Location |
|---|
| Amy Kruse | Director | New York, NY |
| Zia Huque | Director | New York, NY |
| Robert Berman | Director | New York, NY |
| Phil Skolnick | Director | New York, NY |
| Jonathan Sporn | Director | New York, NY |
| Jonathan Sporn | Executive Officer | New York, NY |
| Andrew Kruegel | Director | New York, NY |
| Andrew Kruegel | Executive Officer | New York, NY |
Other filings by this issuer (3)
More